Clinical trials: Ovarian Hyperstimulation
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects
This study is a multi-center, randomized, double-blind, positive drug-controlled, non-inferiority Phase III clinical trial. The study will enroll approximately 316 infertile female subjects undergoing controlled ovarian…
- Trial name
- NCT05994378
- Testing
- SHR7280；Ganirelix Acetate Injection simulant, SHR7280 simulant； Ganirelix Acetate Injection
- Where
- China
- Volunteers
- 317 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
- Trial name
- NCT05738382
- Testing
- BG2109, Cetrorelix
- Where
- 10 sites in China
- Volunteers
- 240 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
Ovarian Hyperstimulation Syndrome (OHSS)
Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.
Ovarian hyper stimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in IVF (In Vitro Fertilisation).
- Trial name
- SHOview (NCT01703728)
- Testing
- Highly purified menotropin (HP- hMG) treatment
- Where
- 20 sites in France
- Volunteers
- 455 people
- Sponsor
- Ferring Pharmaceuticals
Ovarian Hyperstimulation Syndrome
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
The aim of this study was to evaluate the efficacy and safety of domestic recombinant human follicle stimulating hormone (rhFSH) stimulating ovarian to promote follicular development before assisted reproductive technology, which…
- Trial name
- NCT03071172
- Testing
- Triptorelin for Injection, Recombinant Human Choriogonadotropin alfa Solution for Injection, Progesterone Soft Capsules
- Where
- 7 sites in China
- Volunteers
- 252 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Infertility, Monofollicular Development
Low-dose Gonal-f® in Ovulation Induction
This is a prospective, multicenter, open-label, comparative and parallel-group study of ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH) treatment using the Gonal-f® prefilled pen in…
- Trial name
- LoGo (NCT01871532)
- Testing
- Gonal-f®
- Where
- 10 sites in Ireland, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovulation Induction
A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α
This is a prospective and multicentric observational study to determine the real mono-bifollicular development rate that is obtained under normal care conditions following ovulation induction (OI) treatment with follitropin-alpha…
- Trial name
- P450 (NCT01111084)
- Testing
- Follitropin alpha (r-FSH)
- Where
- Spain
- Volunteers
- 410 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multifollicular Stimulation
An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen
This is a prospective, observational and multicentric study to compare the Gonal-f FbM (filled by mass) dose prescribed by the doctor with the Gonal-f FbM dose determined by the CONSORT (Consistency in r-FSH Starting doses for…
- Trial name
- NCT01080729
- Testing
- Recombinant-follicle stimulating hormone (r-FSH)
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Hyperstimulation Syndrome
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
- Trial name
- NCT00329693
- Testing
- Norprolac
- Where
- 7 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals